ISSN: 1838-7640Theranostics
Global reach, higher impact
Theranostics 2024; 14(3):988-1009. doi:10.7150/thno.89602 This issue Cite
Research Paper
Palmitoylation of PKCδ by ZDHHC5 in hypothalamic microglia presents as a therapeutic target for fatty liver disease
1. State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China.
2. Department of Neurosurgery, Peking University Third Hospital, Beijing 100191, China.
3. School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing 100102, China.
4. Proteomics Laboratory, Medical and Healthy Analytical Center, Peking University Health Science Center, Beijing 100191, China.
*Lead Contact.
Citation:
Wang YH, Chen X, Bai YZ, Gao P, Yang Z, Guo Q, Lu YY, Zheng J, Liu D, Yang J, Tu PF, Zeng KW. Palmitoylation of PKCδ by ZDHHC5 in hypothalamic microglia presents as a therapeutic target for fatty liver disease. Theranostics 2024; 14(3):988-1009. doi:10.7150/thno.89602. https://www.thno.org/v14p0988.htm
Other stylesAbstract
The hypothalamus plays a fundamental role in controlling lipid metabolism through neuroendocrine signals. However, there are currently no available drug targets in the hypothalamus that can effectively improve human lipid metabolism. In this study, we found that the antimalarial drug artemether (ART) significantly improved lipid metabolism by specifically inhibiting microglial activation in the hypothalamus of high-fat diet-induced mice. Mechanically, ART protects the thyrotropin-releasing hormone (TRH) neurons surrounding microglial cells from inflammatory damage and promotes the release of TRH into the peripheral circulation. As a result, TRH stimulates the synthesis of thyroid hormone (TH), leading to a significant improvement in hepatic lipid disorders. Subsequently, we employed a biotin-labeled ART chemical probe to identify the direct cellular target in microglial cells as protein kinase Cδ (PKCδ). Importantly, ART directly targeted PKCδ to inhibit its palmitoylation modification by blocking the binding of zinc finger DHHC-type palmitoyltransferase 5 (ZDHHC5), which resulted in the inhibition of downstream neuroinflammation signaling. In vivo, hypothalamic microglia-specific PKCδ knockdown markedly impaired ART-dependent neuroendocrine regulation and lipid metabolism improvement in mice. Furthermore, single-cell transcriptomics analysis in human brain tissues revealed that the level of PKCδ in microglia positively correlated with individuals who had hyperlipemia, thereby highlighting a clinical translational value. Collectively, these data suggest that the palmitoylation of microglial PKCδ in the hypothalamus plays a role in modulating peripheral lipid metabolism through hypothalamus-liver communication, and provides a promising therapeutic target for fatty liver diseases.
Keywords: hepatic lipid metabolism, protein kinase Cδ (PKCδ), palmitoylation modification, hypothalamic microglia, artemether
Citation styles
APA
Wang, Y.H., Chen, X., Bai, Y.Z., Gao, P., Yang, Z., Guo, Q., Lu, Y.Y., Zheng, J., Liu, D., Yang, J., Tu, P.F., Zeng, K.W. (2024). Palmitoylation of PKCδ by ZDHHC5 in hypothalamic microglia presents as a therapeutic target for fatty liver disease. Theranostics, 14(3), 988-1009. https://doi.org/10.7150/thno.89602.
ACS
Wang, Y.H.; Chen, X.; Bai, Y.Z.; Gao, P.; Yang, Z.; Guo, Q.; Lu, Y.Y.; Zheng, J.; Liu, D.; Yang, J.; Tu, P.F.; Zeng, K.W. Palmitoylation of PKCδ by ZDHHC5 in hypothalamic microglia presents as a therapeutic target for fatty liver disease. Theranostics 2024, 14 (3), 988-1009. DOI: 10.7150/thno.89602.
NLM
Wang YH, Chen X, Bai YZ, Gao P, Yang Z, Guo Q, Lu YY, Zheng J, Liu D, Yang J, Tu PF, Zeng KW. Palmitoylation of PKCδ by ZDHHC5 in hypothalamic microglia presents as a therapeutic target for fatty liver disease. Theranostics 2024; 14(3):988-1009. doi:10.7150/thno.89602. https://www.thno.org/v14p0988.htm
CSE
Wang YH, Chen X, Bai YZ, Gao P, Yang Z, Guo Q, Lu YY, Zheng J, Liu D, Yang J, Tu PF, Zeng KW. 2024. Palmitoylation of PKCδ by ZDHHC5 in hypothalamic microglia presents as a therapeutic target for fatty liver disease. Theranostics. 14(3):988-1009.
This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.